Matthew Worrall Director, Corporate Communications and Public Affairs, Ferring +447442 271811 Matthew.Worrall@ferring.com Tomas de Wouters CEO, PharmaBiome +41 44 552 03 04 media@pharmabiome.com ...

PARSIPPANY, N.J., Nov. 29, 2017 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has granted Ferring Pharmaceuticals Inc. approval to market CLENPIQ™ (sodium picosulfate, magnesium ...

Ferring Pharmaceuticals and Posterity Health, a male fertility center of excellence, have partnered to launch a male fertility program. The two organizations announced the program’s debut on Thursday ...

Contacts. For more information: Bhavin Vaid Head of Corporate Communications +41 58 301 0952 (direct) +41 79 191 0632 (mobile) bhavin.vaid@ferring.com Victoria Buenemann Communications & Business ...

Ferring Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved ZOMACTON (somatropin) for injection in four additional pediatric indications: ...

Ferring Pharmaceuticals is setting the record straight on fertility issues. Because infertility is often branded largely as a women’s issue, many men may be unaware of their own possible role in ...

Ferring Pharmaceuticals has acquired exclusive licensing rights to the Phase III radicular leg pain candidate SI-6603 (condoliase) from Seikagaku, the companies said today. Seikagaku said the deal ...

The U.S. Food and Drug Administration on Friday approved Swiss drugmaker Ferring Pharmaceuticals' first gene therapy for treating adult patients with a type of bladder cancer.

Ferring Inc. logo (CNW Group/Ferring Inc.) C. diff is the most common cause of infectious diarrhea in hospitalized patients in the industrialized world, including Canada. 2 Once a person has an ...

RELATED: Ferring's C. difficile drug overcomes skepticism to secure FDA committee nod C. diff. is a superbug that resists antibiotics and other medications. The disorder causes roughly 500,000 ...

Ferring Pharmaceuticals’ chief operating officer and president of its executive board, Michel Pettigrew, announced that he plans to retire Dec. 31. Chief Science Officer Per Falk, M.D., Ph.D ...

Ferring Pharmaceuticals’ new manufacturing facility in Parsippany, NJ. Is there virtue in obscurity? As media and investor coverage of biopharmaceuticals skirts closer to tabloid fodder, it’s a ...